Advertisement

Advertisement
Palliative Care

Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates

Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring...

Global Cancer Care

How ASCO’s Regional Councils Are Having an International Impact on Patients With Cancer

In September 2023, ASCO announced the establishment of its fourth regional council, the Central and Eastern European Regional Council, which includes representatives...

Multiple Myeloma

Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance

About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial...


Advertisement
Issues in Oncology
Lung Cancer

Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies

In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD)...

Lung Cancer

First-Line Radioligand-Based Therapy Demonstrates Benefit in Some Neuroendocrine Tumors

Adding the radioligand lutetium-177 dotatate (Lu-177 dotatate) to standard therapy almost tripled the median progression-free survival in patients with untreated, high-grade...

Advertisement
Advertisement





Lung Cancer

Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease

Bladder Cancer
Immunotherapy

Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer: KEYNOTE-057

As reported in The Lancet Oncology by Arjun V. Balar, MD, and colleagues, the phase II KEYNOTE-057 trial showed that pembrolizumab produced enduring responses in a cohort of patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) who were ineligible ...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Immunotherapy

Michel Sadelain, MD, PhD, on the Road to Synthetic Immunity: Novel CAR Designs

Skin Cancer
Immunotherapy

Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...

Breast Cancer

Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer

In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine

Leukemia
Immunotherapy

Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL

The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter